Gino Santini - Net Worth and Insider Trading

Gino Santini Net Worth

The estimated net worth of Gino Santini is at least $46 Million dollars as of 2023-06-09. Gino Santini is the Sr.VP, Corp. Strategy & Policy of Eli Lilly and Co and owns about 89,010 shares of Eli Lilly and Co (LLY) stock worth over $40 Million. Gino Santini is also the Director of Horizon Therapeutics PLC and owns about 63,303 shares of Horizon Therapeutics PLC (HZNP) stock worth over $6 Million. Details can be seen in Gino Santini's Latest Holdings Summary section.

Transaction Summary of Gino Santini

Gino Santini Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gino Santini owns 7 companies in total, including Horizon Therapeutics PLC (HZNP) , AMAG Pharmaceuticals Inc (AMAG) , and Intercept Pharmaceuticals Inc (ICPT) among others .

Click here to see the complete history of Gino Santini’s form 4 insider trades.

Insider Ownership Summary of Gino Santini

Ticker	Comapny	Transaction Date	Type of Owner
HZNP	Horizon Therapeutics PLC	2012-03-06	director
AMAG	AMAG Pharmaceuticals Inc	2020-06-02	director
ICPT	Intercept Pharmaceuticals Inc	2020-05-28	director
COLL	Collegium Pharmaceutical Inc	2022-05-19	director
ALNAQ	Allena Pharmaceuticals Inc	2017-11-01	director
VTAE	Vitae Pharmaceuticals Inc	2016-10-25	director
LLY	Eli Lilly and Co	2004-01-01	President & US Operations

Gino Santini Latest Holdings Summary

Gino Santini currently owns a total of 2 stocks. Among these stocks, Gino Santini owns 89,010 shares of Eli Lilly and Co (LLY) as of December 15, 2005, with a value of $40 Million and a weighting of 86.31%. Gino Santini also owns 63,303 shares of Horizon Therapeutics PLC (HZNP) as of March 1, 2021, with a value of $6 Million and a weighting of 13.69%.

Latest Holdings of Gino Santini

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
LLY	Eli Lilly and Co	2005-12-15	89,010	445.66	39,668,197
HZNP	Horizon Therapeutics PLC	2021-03-01	63,303	99.42	6,293,584

Holding Weightings of Gino Santini

Gino Santini Form 4 Trading Tracker

According to the SEC Form 4 filings, Gino Santini has made a total of 0 transactions in Eli Lilly and Co (LLY) over the past 5 years. The most-recent trade in Eli Lilly and Co is the sale of 5,000 shares on December 15, 2005, which brought Gino Santini around $280,700.

According to the SEC Form 4 filings, Gino Santini has made a total of 1 transactions in Horizon Therapeutics PLC (HZNP) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Horizon Therapeutics PLC is the sale of 12,000 shares on March 1, 2021, which brought Gino Santini around $1 Million.

Insider Trading History of Gino Santini

Ticker
HZNP
LLY
LLY

Ticker	Company	Date	Buy/Sell	Insider Trading Shares	Shares Change	Price	Cost	Final Share	Current Price	Price Change Since Insider Trade (%)	Filing Date
HZNP	Horizon Therapeutics PLC	2021-03-01	Sell	12,000.00	-15.94%	$91.47	$1,097,640.00	63,303.00	$99.42	8.69%	-
LLY	Eli Lilly and Co	2005-12-15	Sell	5,000.00	-5.32%	$56.14	$280,700.00	89,010.00	$445.66	693.84%	-
LLY	Eli Lilly and Co	2005-02-07	Sell	6,000.00	-6.75%	$56.00	$336,000.00	82,950.00	$445.66	695.82%	-

Total 3

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Gino Santini Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Gino Santini Ownership Network

Ownership Network List of Gino Santini

No Data

Ownership Network Relation of Gino Santini

Gino Santini Owned Company Details

What does Horizon Therapeutics PLC do?

Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.

Who are the key executives at Horizon Therapeutics PLC?

Gino Santini is the director of Horizon Therapeutics PLC. Other key executives at Horizon Therapeutics PLC include Chief Accounting Officer Patrick Mcilvenny , Chief Commercial Officer Jacopo Leonardi , and EVP & Chief Financial Officer Aaron Cox .

Horizon Therapeutics PLC (HZNP) Insider Trades Summary

Over the past 18 months, Gino Santini made no insider transaction in Horizon Therapeutics PLC (HZNP). Other recent insider transactions involving Horizon Therapeutics PLC (HZNP) include a net sale of 600,000 shares made by Timothy P Walbert , a net sale of 72,210 shares made by Andy Pasternak , and a net sale of 405,553 shares made by Paul W. Hoelscher .

In summary, during the past 3 months, insiders sold 0 shares of Horizon Therapeutics PLC (HZNP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,265,596 shares of Horizon Therapeutics PLC (HZNP) were sold and 745 shares were bought by its insiders, resulting in a net sale of 1,264,851 shares.

Horizon Therapeutics PLC (HZNP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Horizon Therapeutics PLC Insider Transactions

No Available Data

What does AMAG Pharmaceuticals Inc do?

AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.

Who are the key executives at AMAG Pharmaceuticals Inc?

Gino Santini is the director of AMAG Pharmaceuticals Inc. Other key executives at AMAG Pharmaceuticals Inc include 10 percent owner Camber Capital Management Lp , Chief Operating Officer Anthony Casciano , and Interim CFO Brian Piekos .

AMAG Pharmaceuticals Inc (AMAG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AMAG Pharmaceuticals Inc (AMAG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AMAG Pharmaceuticals Inc (AMAG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AMAG Pharmaceuticals Inc (AMAG)'s detailed insider trading history can be found in Insider Trading Tracker table.

AMAG Pharmaceuticals Inc Insider Transactions

No Available Data

What does Intercept Pharmaceuticals Inc do?

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Who are the key executives at Intercept Pharmaceuticals Inc?

Gino Santini is the director of Intercept Pharmaceuticals Inc. Other key executives at Intercept Pharmaceuticals Inc include EVP & Chief Financial Officer Andrew Saik , President & R&D and CMO M Michelle Berrey , and Chief Accounting Officer Rocco Venezia .

Intercept Pharmaceuticals Inc (ICPT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Intercept Pharmaceuticals Inc (ICPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intercept Pharmaceuticals Inc (ICPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Intercept Pharmaceuticals Inc (ICPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Intercept Pharmaceuticals Inc Insider Transactions

No Available Data

What does Collegium Pharmaceutical Inc do?

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.

Who are the key executives at Collegium Pharmaceutical Inc?

Gino Santini is the director of Collegium Pharmaceutical Inc. Other key executives at Collegium Pharmaceutical Inc include EVP and Chief Medical Officer Thomas B Smith , EVP & Chief Financial Officer Tupper Colleen , and EVP and Chief Medical Officer Richard Malamut .

Collegium Pharmaceutical Inc (COLL) Insider Trades Summary

Over the past 18 months, Gino Santini made no insider transaction in Collegium Pharmaceutical Inc (COLL). Other recent insider transactions involving Collegium Pharmaceutical Inc (COLL) include a net sale of 289,790 shares made by Joseph Ciaffoni , a net sale of 298,612 shares made by Michael Thomas Heffernan , and a net sale of 60,700 shares made by Shirley R. Kuhlmann .

In summary, during the past 3 months, insiders sold 125,087 shares of Collegium Pharmaceutical Inc (COLL) in total and bought 0 shares, with a net sale of 125,087 shares. During the past 18 months, 687,538 shares of Collegium Pharmaceutical Inc (COLL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 687,538 shares.

Collegium Pharmaceutical Inc (COLL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Collegium Pharmaceutical Inc Insider Transactions

No Available Data

What does Allena Pharmaceuticals Inc do?

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

Who are the key executives at Allena Pharmaceuticals Inc?

Gino Santini is the director of Allena Pharmaceuticals Inc. Other key executives at Allena Pharmaceuticals Inc include Chief Financial Officer Richard D Katz , 10 percent owner Frazier Healthcare Vi, L.p. , and 10 percent owner Hbm Biocapital Ii Lp .

Allena Pharmaceuticals Inc (ALNAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Allena Pharmaceuticals Inc (ALNAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Allena Pharmaceuticals Inc (ALNAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Allena Pharmaceuticals Inc (ALNAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Allena Pharmaceuticals Inc Insider Transactions

No Available Data

What does Vitae Pharmaceuticals Inc do?

Vitae Pharmaceuticals Inc was incorporated in Delaware in May 2001. The Company is a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases in which there are significant unmet medical needs. The Company is developing a robust and growing portfolio of novel product candidates internally generated by Contour, its proprietary structure-based drug discovery platform. The Company's product candidate include VTP-43742, a first in class oral small molecule, which is being developed for the treatment of psoriasis as well as multiple autoimmune disorders, and is currently being studied in a Phase 2a proof-of-concept clinical trial. The Company's other product candidate is VTP-38543 for the treatment of atopic dermatitis, which is in Phase 2a clinical development. The Company also has a product candidate, VTP-36951, in pre-clinical development for the treatment and prevention of Alzheimer's disease, or Alzheimer's. In addition to its existing product candidates, it utilizes a structure-based drug discovery platform, and leverage expertise to create novel, potent and selective product candidates. The Company utilizes Contour to discover and develop product candidates for validated therapeutic targets against which the industry has traditionally struggled to develop drugs due to challenges related to potency, selectivity, pharmacokinetics, or patentability issues. Contour's computational software uses artificial intelligence and sophisticated algorithms to model the assembly of molecular fragments, which are chemical structures consisting of one to several atoms, into fully elaborated, drug-like structures that precisely fit each target's 3-dimensional binding site. It faces potential competition from pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions.

Who are the key executives at Vitae Pharmaceuticals Inc?

Gino Santini is the director of Vitae Pharmaceuticals Inc. Other key executives at Vitae Pharmaceuticals Inc include Chief Financial Officer Richard Steven Morris , General Counsel Scott Applebaum , and Chief Medical Officer Carole Sable .

Vitae Pharmaceuticals Inc (VTAE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Vitae Pharmaceuticals Inc (VTAE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vitae Pharmaceuticals Inc (VTAE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Vitae Pharmaceuticals Inc (VTAE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vitae Pharmaceuticals Inc Insider Transactions

No Available Data

What does Eli Lilly and Co do?

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Who are the key executives at Eli Lilly and Co?

Gino Santini is the President & US Operations of Eli Lilly and Co. Other key executives at Eli Lilly and Co include EVP & HR & Diversity Eric Dozier , SVP & CEO LoxoONC & Pres LlyONC Naarden Jacob Van , and SVP & ERM & CECO Alonzo Weems .

Eli Lilly and Co (LLY) Insider Trades Summary

Over the past 18 months, Gino Santini made no insider transaction in Eli Lilly and Co (LLY). Other recent insider transactions involving Eli Lilly and Co (LLY) include a net sale of 5,114,181 shares made by Lilly Endowment Inc , a net sale of 4,860 shares made by Donald A Zakrowski , and a net sale of 2,312 shares made by Alonzo Weems .

In summary, during the past 3 months, insiders sold 1,067,600 shares of Eli Lilly and Co (LLY) in total and bought 0 shares, with a net sale of 1,067,600 shares. During the past 18 months, 5,133,028 shares of Eli Lilly and Co (LLY) were sold and 858 shares were bought by its insiders, resulting in a net sale of 5,132,170 shares.

Eli Lilly and Co (LLY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eli Lilly and Co Insider Transactions

No Available Data

Gino Santini Mailing Address

Above is the net worth, insider trading, and ownership report for Gino Santini. You might contact Gino Santini via mailing address: C/o Amag Pharmaceuticals, Inc., 1100 Winter Street, Waltham Ma 02451.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF ADV Part 2A ADV Part 2B ADV Part 3 Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.